Etienne Daher

Analyste en capital-investissement chez

Aescap Venture Management BV

Finance

Consumer Services

Health Technology

Profil

Mr. Etienne Daher is a Senior Associate at Invus SAS. Prior to joining Invus in 2024, Mr. Daher was a Senior Analyst at Aescap, a public equity investment company focused on biotech.
Previously, Etienne worked as Chief of Staff at biotech company Sensorion and as Startup Manager for healthcare companies at Bpifrance.
He was also employed as an Analyst by Merck Ventures BV.
He holds a PharmD from Université Grenoble Alpes and a Master in Strategy and Management of International Business from ESSEC Business School in France.

Postes actifs de Etienne Daher

Sociétés	Poste	Début
Aescap Venture Management BV Aescap Venture Management BV Investment ManagersFinance Aescap's investment objective is to achieve a high rate of return for their investors while actively developing their portfolio firms' potential for commercial success. They invest in seed, start-up and early-stage biomedical firms based in Europe. They generally take majority stakes. They target firms working on treatment of human diseases. They seek a balanced portfolio composed of 15 to 20 firms. Within the biomedical area, Aescap looks for firms with marketplace leadership potential at a worldwide level. They prefer to invest in products which are sufficiently mature to yield realistic opportunities in the marketplace as well as assuring cash flow from licensing deals. Aescap is an active, hands-on investment partner. They work closely with the portfolio firm's management team to optimize human resources to build the business around innovative research. Aescap generally invests over a time frame of three to six years, depending on the type of investment. They seek transparency in legal and IP structure.	Analyste en capital-investissement	01/06/2021
Invus SAS (Investment Management) Invus SAS (Investment Management) Investment ManagersFinance Invus-IM takes significant, long-term positions in public companies whose fundamentals and management they believe in. They focus on stocks that are trading below the firm's assessment of their intrinsic business value. The average holding period in their public equity portfolio is not measured in weeks or months but years. Leveraging their deep expertise in the healthcare sector, Invus-IM also works with their private equity team jointly investing in Series A and Series B rounds of private biotech companies making transformational bets on the future of healthcare, where they continue to support them as they go public.	Analyst-Equity	01/01/2024

Tous les postes actifs de Etienne Daher

Anciens postes connus de Etienne Daher

Sociétés	Poste	Fin
SENSORION	Corporate Officer/Principal	01/05/2021
Merck Ventures BV Merck Ventures BV Investment ManagersFinance Merck Ventures invests in companies located in the Netherlands. The firm targets companies operating in the fields of healthcare, healthcare drug development, life science tools, electronics and frontier technology & sustainability sectors. It provides financing for early stage capital requirements.	Analyste en capital-investissement	31/12/2017

Voir l'expérience en détail de Etienne Daher

Formation de Etienne Daher

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de Etienne Daher

Relations

Relations au 1er degré

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Entreprise privées	5
ESSEC Business School ESSEC Business School Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Aescap Venture Management BV Aescap Venture Management BV Investment ManagersFinance Aescap's investment objective is to achieve a high rate of return for their investors while actively developing their portfolio firms' potential for commercial success. They invest in seed, start-up and early-stage biomedical firms based in Europe. They generally take majority stakes. They target firms working on treatment of human diseases. They seek a balanced portfolio composed of 15 to 20 firms. Within the biomedical area, Aescap looks for firms with marketplace leadership potential at a worldwide level. They prefer to invest in products which are sufficiently mature to yield realistic opportunities in the marketplace as well as assuring cash flow from licensing deals. Aescap is an active, hands-on investment partner. They work closely with the portfolio firm's management team to optimize human resources to build the business around innovative research. Aescap generally invests over a time frame of three to six years, depending on the type of investment. They seek transparency in legal and IP structure.	Finance
Sensorion SA Sensorion SA Pharmaceuticals: MajorHealth Technology Operates as a research and development company that discovers drugs to treat inner ear disorders	Health Technology
Invus SAS (Investment Management) Invus SAS (Investment Management) Investment ManagersFinance Invus-IM takes significant, long-term positions in public companies whose fundamentals and management they believe in. They focus on stocks that are trading below the firm's assessment of their intrinsic business value. The average holding period in their public equity portfolio is not measured in weeks or months but years. Leveraging their deep expertise in the healthcare sector, Invus-IM also works with their private equity team jointly investing in Series A and Series B rounds of private biotech companies making transformational bets on the future of healthcare, where they continue to support them as they go public.	Finance
Merck Ventures BV Merck Ventures BV Investment ManagersFinance Merck Ventures invests in companies located in the Netherlands. The firm targets companies operating in the fields of healthcare, healthcare drug development, life science tools, electronics and frontier technology & sustainability sectors. It provides financing for early stage capital requirements.	Finance